Venture Capital

Updated:

Particular Ventures

Particular Ventures operates as a closely held angel fund concentrating pre-seed and seed capital on consumer-facing medical devices and digital health.

Particular Ventures logo

Particular Ventures

Particular Ventures invests in pre-seed and seed stage medical technology companies. Their focus includes medical devices, digital health, wearables, and consumerized healthcare. The firm has made 27 investments, including a seed investment in Ultralight on May 29, 2024.

General information

Firm type

Venture Capital

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

San Francisco

Corporate office

San Francisco, CA, United States

Sector focus

Medical DevicesDigital HealthWearablesConsumer Health

Frequently asked questions

What investment stages does Particular Ventures target?

The firm writes pre-seed and seed-stage checks, which it describes as belief capital. It does not disclose check sizes or reserve allocation. Its public materials do not reference follow-on investing or later-stage participation.

Which sectors does Particular Ventures explicitly avoid?

The investment thesis requires a consumer-facing medical device, wearable, or digital health product with a user experience element. Enterprise health IT, provider-focused software, therapeutics, diagnostics without a patient interface, and non-healthcare technology fall outside this mandate.

How is Particular Ventures structured — is it a fund or an angel syndicate?

The firm styles itself as a closely held angel fund rather than an institutional venture vehicle. It does not disclose its legal structure, fund vehicles, or whether it operates as a general partnership, limited partnership, or single-investor entity.

Has Particular Ventures produced liquidity for its investors?

The disclosed portfolio includes three acquisitions: Tueo Health (by Apple in 2018), Blumio (by CardieX in 2022), and Ultralight (by Greenlight Guru in 2025). Clover Health went public via SPAC in 2021. Several portfolio companies ceased operations between 2021 and 2025, including metaMe Health and TriVirum.

Who makes investment decisions at Particular Ventures?

No investment professionals, investment committee members, or managing principals are named on the firm's website or in its public materials. The decision-making structure is not publicly disclosed.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on venture capital firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More San Francisco Venture Capital profiles